JP6783596B2 - 分析物質の濃度予測方法および装置 - Google Patents
分析物質の濃度予測方法および装置 Download PDFInfo
- Publication number
- JP6783596B2 JP6783596B2 JP2016179957A JP2016179957A JP6783596B2 JP 6783596 B2 JP6783596 B2 JP 6783596B2 JP 2016179957 A JP2016179957 A JP 2016179957A JP 2016179957 A JP2016179957 A JP 2016179957A JP 6783596 B2 JP6783596 B2 JP 6783596B2
- Authority
- JP
- Japan
- Prior art keywords
- concentration
- section
- learning
- analytical substance
- spectra
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000126 substance Substances 0.000 title claims description 141
- 238000000034 method Methods 0.000 title claims description 48
- 238000001228 spectrum Methods 0.000 claims description 139
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 65
- 239000008103 glucose Substances 0.000 claims description 65
- 230000008859 change Effects 0.000 claims description 61
- 238000001727 in vivo Methods 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 10
- 239000012491 analyte Substances 0.000 claims description 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 238000004891 communication Methods 0.000 claims description 7
- 239000004202 carbamide Substances 0.000 claims description 6
- 235000012000 cholesterol Nutrition 0.000 claims description 6
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 244000005700 microbiome Species 0.000 claims description 5
- 238000000862 absorption spectrum Methods 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 239000008280 blood Substances 0.000 description 49
- 210000004369 blood Anatomy 0.000 description 49
- 230000003595 spectral effect Effects 0.000 description 10
- 238000005259 measurement Methods 0.000 description 8
- 238000010586 diagram Methods 0.000 description 6
- 235000003642 hunger Nutrition 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 238000004364 calculation method Methods 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 238000004566 IR spectroscopy Methods 0.000 description 4
- 238000001069 Raman spectroscopy Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 238000000513 principal component analysis Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- KVZLHPXEUGJPAH-UHFFFAOYSA-N 2-oxidanylpropanoic acid Chemical compound CC(O)C(O)=O.CC(O)C(O)=O KVZLHPXEUGJPAH-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0075—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1495—Calibrating or testing of in-vivo probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7264—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems
- A61B5/7267—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems involving training the classification device
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/4833—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
- A61B2560/02—Operational features
- A61B2560/0223—Operational features of calibration, e.g. protocols for calibrating sensors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2201/00—Features of devices classified in G01N21/00
- G01N2201/12—Circuits of general importance; Signal processing
- G01N2201/129—Using chemometrical methods
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Artificial Intelligence (AREA)
- Signal Processing (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Chemical & Material Sciences (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Computation (AREA)
- Fuzzy Systems (AREA)
- Mathematical Physics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Data Mining & Analysis (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Databases & Information Systems (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Description
110 区間決定部、
120 学習部、
130 濃度予測部、
140 通信部、
150 光学センサ。
Claims (27)
- 体内に含まれている分析物質の濃度を予測する方法であって、
前記分析物質に対する複数の体内スペクトルを取得する段階と、
前記分析物質の濃度が実質的に変化しない区間および前記複数の体内スペクトルに基づいて、前記分析物質に対する濃度予測アルゴリズムの学習区間を決定する段階と、
前記学習区間に対する学習結果および前記分析物質の固有スペクトルに基づいて、前記濃度予測アルゴリズムを用いて前記分析物質の濃度を予測する段階と、を含み、
前記学習区間を決定する段階は、
前記複数の体内スペクトル間の類似度を計算する段階と、
前記類似度が高い区間を類似区間として決定する段階と、
前記分析物質の濃度が実質的に変化しない区間と前記類似区間との重なる区間を前記学習区間として決定する段階と、
を含む分析物質の濃度予測方法。 - 前記分析物質は、ブドウ糖、尿素、乳酸、トリグリセリド、蛋白質、コレステロール、またはエタノールのうちの少なくとも1つである、請求項1に記載の分析物質の濃度予測方法。
- 前記分析物質は、ブドウ糖であり、前記分析物質の濃度が実質的に変化しない区間は、空腹区間である、請求項1に記載の分析物質の濃度予測方法。
- 前記体内スペクトルは、赤外線の吸収スペクトルまたは反射スペクトルのうちの1つである、請求項1に記載の分析物質の濃度予測方法。
- 前記体内スペクトルは、単一波長の電磁波の散乱スペクトルである、請求項1に記載の分析物質の濃度予測方法。
- 前記取得する段階は、予め設定された時間間隔に応じて連続的に前記複数の体内スペクトルを取得する段階を含む、請求項1に記載の分析物質の濃度予測方法。
- 前記濃度予測アルゴリズムは、純分析物質信号(net analyte signal、NAS)アルゴリズムである、請求項1に記載の分析物質の濃度予測方法。
- 前記類似度を計算する段階は、
前記複数の体内スペクトルのうち、相互類似度を計算する少なくとも2つのスペクトルに対して基準線を整列する段階と、
前記基準線が整列された前記少なくとも2つの体内スペクトル間の差を計算する段階と 、
を含む、請求項1に記載の分析物質の濃度予測方法。 - 前記予測する段階は、
前記学習区間の長さが予め設定された区間の長さより長い場合に、前記学習区間を含む前記類似区間に対する前記分析物質の濃度を予測する段階を含む、請求項1に記載の分析物質の濃度予測方法。 - 前記予測する段階は、
前記学習区間の長さが予め設定された長さより短い場合に、前記学習区間を含む前記類似区間で追加的に学習区間を決定する段階を含む、請求項1に記載の分析物質の濃度予測方法 。 - 前記予測する段階は、
前記学習区間の長さが予め設定された長さより短い場合に、濃度予測不可を知らせるメッセージを使用者に表示する段階を含む、請求項1に記載の分析物質の濃度予測方法。 - 前記分析物質は、人体、動物、哺乳類、非哺乳類または微生物のうちの1つに含まれている分析物質である、請求項1に記載の分析物質の濃度予測方法。
- 体内に含まれている分析物質の濃度予測装置であって、
少なくとも1つのプロセッサと、
メモリと、を含み、
前記少なくとも1つのプロセッサは、前記メモリに保存された少なくとも1つのプログラムを実行して、
前記分析物質に対する複数の体内スペクトルを取得する段階と、
前記分析物質の濃度が実質的に変化しない区間および前記複数の体内スペクトルに基づいて、前記分析物質に対する濃度予測アルゴリズムの学習区間を決定する段階と、
前記学習区間に対する学習結果および前記分析物質の固有スペクトルに基づいて、前記濃度予測アルゴリズムを用いて前記分析物質の濃度を予測する段階と、を行い、
前記少なくとも1つのプロセッサは、前記学習区間を決定する段階を行う時、
前記複数の体内スペクトル間の類似度を計算する段階と、
前記類似度が高い区間を類似区間として決定する段階と、
前記分析物質の濃度が実質的に変化しない区間と前記類似区間との重なる区間を前記学習区間として決定する段階と、
を行う濃度予測装置。 - 前記分析物質は、ブドウ糖、尿素、乳酸、トリグリセリド、蛋白質、コレステロール、またはエタノールのうちの少なくとも1つである、請求項13に記載の濃度予測装置。
- 前記分析物質は、ブドウ糖であり、前記分析物質の濃度が実質的に変化しない区間は、空腹区間である、請求項13に記載の濃度予測装置。
- 前記体内スペクトルは、赤外線の吸収スペクトルまたは反射スペクトルのうちの1つである、請求項13に記載の濃度予測装置。
- 前記体内スペクトルは、単一波長の電磁波の散乱スペクトルである、請求項13に記載の濃度予測装置。
- 前記少なくとも1つのプロセッサは、前記取得する段階を行う時、
予め決定された時間間隔で連続的に前記複数の体内スペクトルを取得する段階を行う、請求項13に記載の濃度予測装置。 - 前記濃度予測アルゴリズムは、純分析物質信号(net analyte signal、NAS)アルゴリズムである、請求項13に記載の濃度予測装置。
- 前記少なくとも1つのプロセッサは、前記類似度を計算する段階を行う時、
前記複数の体内スペクトルのうち、相互類似度を計算する少なくとも2つのスペクトルに対して基準線を整列する段階と、
前記基準線が整列された前記少なくとも2つの体内スペクトル間の差を計算する段階と 、を行う、請求項13に記載の濃度予測装置。 - 前記少なくとも1つのプロセッサは、前記予測する段階を行う時、
前記学習区間の長さが予め設定された区間の長さより長い場合に、前記学習区間を含む前記類似区間に対する前記分析物質の濃度を予測する段階を行う、請求項13に記載の濃度予測装置。 - 前記少なくとも1つのプロセッサは、前記予測する段階を行う時、
前記学習区間の長さが予め設定された長さより短い場合に、前記学習区間を含む前記類似区間で追加的に前記学習区間を決定する段階を行う、請求項13に記載の濃度予測装置。 - 前記少なくとも1つのプロセッサは、前記予測する段階を行う時、
前記学習区間の長さが予め設定された長さより短い場合に、濃度予測不可を知らせるメッセージを使用者に表示する段階を行う、請求項13に記載の濃度予測装置。 - 前記分析物質は、人体、動物、哺乳類、非哺乳類、または微生物のうちの1つに含まれている分析物質である、請求項13に記載の濃度予測装置。
- 有無線ネットワークを介して赤外線センサまたはレーザセンサから前記複数の体内スペクトルを受信する通信部をさらに含む、請求項13に記載の濃度予測装置。
- 人体に赤外線を照射して前記複数の体内スペクトルを生成する赤外線センサをさらに含む、請求項13に記載の濃度予測装置。
- 人体にレーザを照射して前記複数の体内スペクトルを生成するレーザセンサをさらに含む、請求項13に記載の濃度予測装置。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150134872A KR102443262B1 (ko) | 2015-09-23 | 2015-09-23 | 분석물질 농도 예측 방법 및 장치 |
KR10-2015-0134872 | 2015-09-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017060753A JP2017060753A (ja) | 2017-03-30 |
JP6783596B2 true JP6783596B2 (ja) | 2020-11-11 |
Family
ID=56979429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016179957A Active JP6783596B2 (ja) | 2015-09-23 | 2016-09-14 | 分析物質の濃度予測方法および装置 |
Country Status (5)
Country | Link |
---|---|
US (2) | US10881333B2 (ja) |
EP (1) | EP3150122B1 (ja) |
JP (1) | JP6783596B2 (ja) |
KR (1) | KR102443262B1 (ja) |
CN (1) | CN107007254B (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102539142B1 (ko) | 2016-09-05 | 2023-06-01 | 삼성전자주식회사 | 스펙트럼 분석 장치와 방법, 및 혈당 측정 장치 |
KR20180042700A (ko) | 2016-10-18 | 2018-04-26 | 삼성전자주식회사 | 스펙트럼 안정성 모니터링 장치 및 방법 |
KR102655737B1 (ko) | 2016-11-30 | 2024-04-05 | 삼성전자주식회사 | 생체 성분 추정 장치 및 방법 |
KR102539144B1 (ko) | 2017-10-19 | 2023-06-01 | 삼성전자주식회사 | 개인화된 단위 스펙트럼 획득 장치 및 방법과, 생체 성분 추정 장치 및 방법 |
KR102574085B1 (ko) * | 2017-11-29 | 2023-09-04 | 삼성전자주식회사 | 혈당 농도를 예측하는 장치 및 방법 |
KR20200097144A (ko) | 2019-02-07 | 2020-08-18 | 삼성전자주식회사 | 생체정보 추정 장치 및 방법 |
KR20200100997A (ko) | 2019-02-19 | 2020-08-27 | 삼성전자주식회사 | 분석 물질의 농도 추정 장치 및 방법 |
KR20200133525A (ko) * | 2019-05-20 | 2020-11-30 | 삼성전자주식회사 | 생체 정보 추정 모델의 유효성 판단 장치 및 방법 |
KR20200137103A (ko) * | 2019-05-29 | 2020-12-09 | 삼성전자주식회사 | 생체 정보 추정 모델 갱신 장치 및 방법 |
KR102466236B1 (ko) * | 2020-11-17 | 2022-11-15 | ㈜에이치엠이스퀘어 | 단일 파장을 갖는 레이저 조합을 이용한 광음향 진단 장치 및 방법 |
JPWO2023145810A1 (ja) * | 2022-01-28 | 2023-08-03 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002065090A2 (en) | 2001-01-26 | 2002-08-22 | Sensys Medical | Noninvasive measurement of glucose through the optical properties of tissue |
US7098037B2 (en) | 1998-10-13 | 2006-08-29 | Inlight Solutions, Inc. | Accommodating subject and instrument variations in spectroscopic determinations |
US6157041A (en) * | 1998-10-13 | 2000-12-05 | Rio Grande Medical Technologies, Inc. | Methods and apparatus for tailoring spectroscopic calibration models |
US20080184017A1 (en) | 1999-04-09 | 2008-07-31 | Dave Stuttard | Parallel data processing apparatus |
US6645142B2 (en) * | 2000-12-01 | 2003-11-11 | Optiscan Biomedical Corporation | Glucose monitoring instrument having network connectivity |
US6898451B2 (en) * | 2001-03-21 | 2005-05-24 | Minformed, L.L.C. | Non-invasive blood analyte measuring system and method utilizing optical absorption |
US6574490B2 (en) * | 2001-04-11 | 2003-06-03 | Rio Grande Medical Technologies, Inc. | System for non-invasive measurement of glucose in humans |
US20040142403A1 (en) | 2001-08-13 | 2004-07-22 | Donald Hetzel | Method of screening for disorders of glucose metabolism |
US8718738B2 (en) | 2002-03-08 | 2014-05-06 | Glt Acquisition Corp. | Method and apparatus for coupling a sample probe with a sample site |
JP2004321325A (ja) | 2003-04-22 | 2004-11-18 | Matsushita Electric Works Ltd | 血糖値の定量方法 |
US7591801B2 (en) * | 2004-02-26 | 2009-09-22 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US7460895B2 (en) * | 2005-01-24 | 2008-12-02 | University Of Iowa Research Foundation | Method for generating a net analyte signal calibration model and uses thereof |
JP4928849B2 (ja) * | 2006-06-27 | 2012-05-09 | 東芝メディカルシステムズ株式会社 | 非侵襲的測定装置 |
JP2010005047A (ja) | 2008-06-25 | 2010-01-14 | Panasonic Electric Works Co Ltd | 光学式生体成分測定用の検量モデルの作成方法及び非侵襲血糖値測定装置 |
WO2010019919A1 (en) * | 2008-08-14 | 2010-02-18 | University Of Toledo | Multifunctional neural network system and uses thereof for glycemic forecasting |
-
2015
- 2015-09-23 KR KR1020150134872A patent/KR102443262B1/ko active IP Right Grant
-
2016
- 2016-09-14 JP JP2016179957A patent/JP6783596B2/ja active Active
- 2016-09-20 EP EP16189720.2A patent/EP3150122B1/en active Active
- 2016-09-20 US US15/270,812 patent/US10881333B2/en active Active
- 2016-09-23 CN CN201610848249.7A patent/CN107007254B/zh active Active
-
2020
- 2020-11-24 US US17/102,587 patent/US20210076995A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20170079565A1 (en) | 2017-03-23 |
US10881333B2 (en) | 2021-01-05 |
CN107007254A (zh) | 2017-08-04 |
KR102443262B1 (ko) | 2022-09-13 |
JP2017060753A (ja) | 2017-03-30 |
EP3150122A1 (en) | 2017-04-05 |
KR20170035675A (ko) | 2017-03-31 |
EP3150122B1 (en) | 2022-02-16 |
US20210076995A1 (en) | 2021-03-18 |
CN107007254B (zh) | 2021-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6783596B2 (ja) | 分析物質の濃度予測方法および装置 | |
JP6947531B2 (ja) | 濃度予測方法、濃度予測プログラム、および濃度予測装置 | |
AU754677B2 (en) | System and method for noninvasive blood analyte measurements | |
KR102630877B1 (ko) | 레이저 유도 붕괴 스펙트럼 분석을 이용하는 진단 방법 및 이를 수행하는 진단 장치 | |
US6675029B2 (en) | Apparatus and method for quantification of tissue hydration using diffuse reflectance spectroscopy | |
EP1250082B1 (en) | Classification and characterization of tissue through features related to adipose tissue | |
Chen et al. | Diagnosis of colorectal cancer by near-infrared optical fiber spectroscopy and random forest | |
JP6775660B2 (ja) | 多位置拡散スペクトルデータの処理、モデリング、予測方法および処理装置 | |
JP6462585B2 (ja) | 医学的測定曲線の評価方法 | |
Allegrini et al. | An integrated approach to the simultaneous selection of variables, mathematical pre-processing and calibration samples in partial least-squares multivariate calibration | |
de Souza Gondim et al. | Determining performance parameters in qualitative multivariate methods using probability of detection (POD) curves. Case study: Two common milk adulterants | |
Suryakala et al. | Investigation of goodness of model data fit using PLSR and PCR regression models to determine informative wavelength band in NIR region for non-invasive blood glucose prediction | |
Solihin et al. | Non-invasive blood glucose estimation using handheld near infra-red device | |
Tian et al. | WSPXY combined with BP-ANN method for hemoglobin determination based on near-infrared spectroscopy | |
Sa et al. | Mid-infrared spectroscopy with an effective variable selection method based on mpa for glucose detection | |
Watté et al. | Robust metamodel-based inverse estimation of bulk optical properties of turbid media from spatially resolved diffuse reflectance measurements | |
KR20200047981A (ko) | 생체성분 추정 장치 및 방법 | |
KR102461185B1 (ko) | 스펙트럼 분석법을 이용한 혈중 성분 수치의 추정 장치 | |
CN113692530A (zh) | 用于非侵入式血糖水平估计的便携式设备和方法 | |
Bai et al. | Assessing and advancing technology for the noninvasive measurement of clinical glucose | |
Chauchard et al. | Localization of embedded inclusions using detection of fluorescence: Feasibility study based on simulation data, LS-SVM modeling and EPO pre-processing | |
US11169161B2 (en) | Device, system and method for determining a fibrinogen level in a blood sample | |
Chen et al. | determination of butylated hydroxytoluene in edible oil using near-infrared spectroscopy combined with multivariate analysis | |
Malik et al. | Determination of glucose concentration from near-infrared spectra using locally weighted partial least square regression | |
Xu et al. | An Objective Wavelength Selection Method Based on Moving Window Partial Least Squares for Near-Infrared Spectroscopy. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190527 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200528 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200623 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200923 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201013 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201022 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6783596 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |